Clinical Scorecard: Effect of Socioeconomic Status on SGLT2 Initiation in Heart Failure
At a Glance
| Category | Detail |
|---|---|
| Condition | Heart Failure |
| Key Mechanisms | Socioeconomic factors influencing SGLT2 inhibitor initiation. |
| Target Population | Patients with heart failure in Germany. |
| Care Setting | Retrospective analysis of health insurance claims data. |
Key Highlights
- Only 14.2% of treatment-naive patients initiated SGLT2 inhibitors in 2023.
- Higher income tax municipalities showed greater treatment initiation rates.
- Female patients were less likely to receive SGLT2 inhibitors compared to males.
- Newly coded heart failure and enrollment in disease management programs increased likelihood of initiation.
- Socioeconomic and demographic disparities were noted in treatment initiation.
Guideline-Based Recommendations
Diagnosis
- Identify heart failure patients using administrative coding.
Management
- Consider socioeconomic factors when initiating SGLT2 inhibitors.
Monitoring & Follow-up
- Evaluate treatment initiation rates across different demographics.
Risks
- Potential selection bias due to exclusion of patients with missing information.
Patient & Prescribing Data
68,426 treatment-naive patients with heart failure.
Socioeconomic disadvantages may hinder SGLT2 inhibitor initiation.
Clinical Best Practices
- Implement targeted interventions to address socioeconomic disparities.
- Monitor treatment initiation rates to identify at-risk populations.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
